Class IA PI3Ks are heterodimers with a regulatory (p85α, p85β, or p55γ) and a catalytic subunit (p110α, β, or δ, which give their name to a complex). They make the signaling lipid PIP~3~ that is sensed by a range of effectors \[e.g., protein kinase B (PKB), Bruton's tyrosine kinase (BTK), PIP3-dependent Rac exchange factor 1 (PRex1), PRex1\] that control metabolism, the cytoskeleton, and growth. Genetic alterations that augment the activity of this network can advantage the survival of cancer cells and, consequently, the class I PI3K network is one of the most frequently mutated in cancer ([@r1]).

Work in the 1980s showed that the p85s and p110s bind "nonselectively" ([@r2]) and created the dogma that the relative abundance of the heterodimers is a function of their concentrations.

Class IA PI3Ks are activated by a variety of mechanisms, most characteristically by binding of the SH2 domains in p85s to "YXXM" phospho-tyrosines, in receptor tyrosine kinases (RTKs), their substrates, or adaptors ([@r3]). Dogma suggests that the properties of the SH2 domains in p85α and β are sufficiently similar to drive parallel recruitment of p85s (despite exceptions, e.g., refs. [@r4] and [@r5]).

A number of subunit and isoform specific interactions have been defined that underlie differences in the activation of the heterodimers; e.g., via the Ras Binding Domains (RBDs) in p110s \[p110α binds GTP-Ras- and p110β binds GTP-Rac/CDC42-family members ([@r6], [@r7])\] or the p110's connections with the regulatory subunit's SH2 domains \[p110β and p110δ interact with both SH2 domains while p110α only binds the *N*-SH2 ([@r8])\].

Analysis of wild-type and "oncomutant" class IA PI3Ks has revealed the principles governing their activation ([@r8], [@r9]). Interactions between the p85 subunits' inter-SH2 domain with the p110s' C2 domain, and the p85 subunits' *N*-SH2 domain with the p110s' helical, C2, and kinase domains inhibit kinase activity. In PI3Kβ and δ only, a contact between the C-SH2 and kinase domains also contributes ([@r10]). Phospho-tyrosine binding relieves inhibition by p85s. Class I PI3K activity is ultimately regulated by conformational transitions that increase membrane association and access to PI(4,5)P~2~-substrate ([@r11]). Oncomutations mimick or facilitate the activation process in different ways ([@r12], [@r13]).

The class IA PI3K subunits are differentially expressed; p110δ is abundant in immune cells, the remainder are ubiquitously but differentially expressed.

Work with PI3K inhibitors and GM-mice has cataloged p110-specific signaling in health and disease ([@r1], [@r14]). It is argued this arises because of differences in the properties and/or concentrations of p110s. However, this relies on the dogmas that there is little intersubunit selectivity and/or that p85s do not introduce specificity. The first of these assumptions has not been tested directly and the latter is contradicted by reports of differences in the properties of p85α and p85β ([@r4], [@r5], [@r15], [@r16]).

The concepts of p110-free and p110-independent functions of p85s have been raised many times, including a recent report that *PIK3R1* (encoding p85α) can be a tumor suppressor ([@r17][@r18][@r19][@r20][@r21]--[@r22]) and evidence that p110-free p85s are targeted for isoform-specific degradation ([@r18], [@r23]). Some work has provided evidence for specific p110-free regulatory subunit complexes ([@r19]); however, the best quantitative analysis of class IA PI3K subunit stoichiometry concluded there were no p110-free regulatory subunits ([@r24]). We have addressed these questions/debates.

Results {#s1}
=======

We used standard homologous targeting technology in mouse ES cells to derive mouse strains expressing; either the biotin ligase mBirA \[the prokaryotic biotin ligase BirA modified to have mammalized codon usage ([@r25])\] from the endogenous ROSA26 locus (mBirA^+/+^) or endogenous, C-terminal avi-tagged \[17aa, containing a 15aa minimal consensus for BirA ([@r26])\] p85α, p85β, p110α, p110β, or p110δ (e.g., p85α^avi/avi^, which will tag all three splice-variants of p85α), all in a C57BL/6J background ([*SI Appendix*, Figs. S1--S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). The mice were interbred to express mBirA or the avi-tagged alleles alone or together (e.g., mBirA^+/+^, p85α^avi/avi^ x mBirA^+/+^). All of these strains appeared healthy and fertile except p110α^avi/avi^--mice that did not reach adulthood. The majority died just before birth \[p110α^KD/KD^ mice die near E10 ([@r27])\]. It seems likely, on the basis of the results below, that this problem is due to the C-terminal avi-tag reducing, but not ablating, the kinase activity of p110α; a phenomenon that has been reported before for other C-terminal tags ([@r28]). We derived MEFs from mice expressing each of the avi-tagged subunits and introduced mBirA (or not) and EGFP via viral transduction and sorted EGFP-positive cells for experiments ([Fig. 1*A*](#fig01){ref-type="fig"}).

![Absolute quantitation of class IA PI3K subunits and heterodimers in MEFs. (*A*) Immunoblot of endogenous p85α in lysates of MEFs (clones 1 or 2, genotypes indicated) before (pre) or after (post) pull-down with streptavidin beads. βCOP is a loading control. (*B*) Immunoblots (antibodies noted right) of MEF lysates (genotypes indicated left, all expressing mBirA) before or after pull-down with streptavidin beads compared with aliquots of the bead-wash, the 1^0^ eluate (E1, SDS sample buffer) and 2^0^ eluate (E2). Nonspecific bands are marked \*. (*C*) An anti-avi-immunoblot (fluorescent 2^0^ Ab) of MEF lysates (genotypes indicated). Histogram shows quantification (means ± SD, from two independent MEF clones/genotype) corrected for input protein. (*D*) Absolute quantitation of avi-tagged-PI3K subunits by streptavidin pull-down and mass spec and corrected for input protein (means, ±SD, from two independent clones/genotype, each clone was measured three times, see [*SI Appendix*, Fig. S11](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). (*E*) Absolute levels of the class IA PI3K heterodimers, measured by streptavidin pull-down, from MEF lines expressing avi-tagged p85 (grey bars) or p110 (black) proteins, and mass spec and corrected for input protein (means, ±SD, from two independent MEF clones/genotype, each clone was measured three times). Independent estimates of the amount of each heterodimer are derived from the p85- or p110-directed pull-downs. The underlying data are in [*SI Appendix*, Fig. S11](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental).](pnas.1803446115fig01){#fig01}

Tissue or cell lysates were prepared and subjected to streptavidin-directed pull-down under mild, nondenaturing conditions. Aliquots of the lysates before and after pull-down were immunoblotted with antibodies recognizing: the avi-tag, p85α, p110α, p110β, or p110δ ([Figs. 1 *A--D*](#fig01){ref-type="fig"} and [Fig. 2](#fig02){ref-type="fig"}; see also [*SI Appendix*, Figs. S3--S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). The avi-tagged and/or biotinylated constructs resolved from the endogenous proteins. Firstly, this made it clear, by internal comparison of wild-type and avi-tagged proteins in avi-heterozygous cells/tissues (e.g., p85α-immunoblots of p85α-avi-expressing MEFs, [Fig. 1*A*](#fig01){ref-type="fig"}) or in avi-homozygous cells/tissues (e.g., p110β-immunoblots of p110β-avi-expressing mouse tissues, [Fig. 2](#fig02){ref-type="fig"}) that the presence of the avi-tag had no effect on expression of any of the class IA PI3K subunits (for p85β and p110δ blots, see [*SI Appendix*, Figs. S4 and S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). Secondly, this made it possible to detect complete streptavidin-directed pull-down of avi-tagged, but not wild-type, proteins in the presence, but not the absence, of mBirA ([Fig. 1 *A* and *B*](#fig01){ref-type="fig"}). These latter results demonstrate near 100%, mBirA- and avi-tag-dependent biotinylation and then streptavidin-mediated pull-down.

![Avi-tagging leads to a band-shift but unchanged expression of endogenous p110β in various mouse tissues. Lysates from indicated mouse tissues from p110β^WT/WT^ or p110β^avi/avi^ mice were resolved by SDS/PAGE and immunoblotted with the indicated antibodies.](pnas.1803446115fig02){#fig02}

As the expression of the PI3K subunits was unchanged by avi-tagging, it seemed unlikely their turnover had been perturbed. This was confirmed in "chase" experiments in the presence of an inhibitor of protein synthesis (emetine) with p85α^avi/WT^-MEFs that revealed the rate of degradation of endogenous avi-tagged p85α was indistinguishable from wild-type-p85α in the same cells ([*SI Appendix*, Fig. S8*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). Furthermore, MEFs expressing avi-tagged p85α (p85α^avi/avi^) produced near-identical amounts of PIP~3~, in response to either PDGF or EGF, as wild-type control-MEFs ([*SI Appendix*, Fig. S8*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). Together these results show that avi-tagging the class IA PI3K subunits did not perturb their levels or turnover and had limited effects on function.

Quantification of anti-avi immunoblots revealed that p85α and p110β are the major isoforms of the regulatory and catalytic subunits in MEFs ([Fig. 1*C*](#fig01){ref-type="fig"}), confirming earlier work ([@r24]). We also quantified the expression of the individual avi-tagged subunits in cell lines expressing the relevant avi-tagged proteins by streptavidin pull-down, elution, and mass spectrometry in the presence of multiple, internal, heavy-labeled, synthetic peptide standards to correct for recovery ([Fig. 1*D*](#fig01){ref-type="fig"} and [*SI Appendix*, Figs. S9--S11](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). This confirmed the results with anti-avi immunoblots and indicated the levels of p85α (almost exclusively the largest variant) and p110β to be 58,000 or 42,000 molecules/cell, respectively (intracellular concentrations of 32 or 23 nM). Deeper analysis of these pull-downs (using the heavy-peptide standards) allowed us to quantify all of the other class IA PI3K subunits that were recovered in the pull-downs and hence obtain two (from the p85^avi/avi^ or p110^avi/avi^-pull-downs) independent, direct estimates for the absolute concentration of each heterodimer ([Fig. 1*E*](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S11*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). The relative concentrations of heterodimers were: p85α/p110β \> p85α/p110α = p85β/p110α = p85β/p110β \>\> p85α/p110δ & p85β/p110δ. Very low levels of p55γ were recovered with avi-tagged p110α or β, in keeping with its tissue distribution. The results also indicate that the avi-tags had minimal impact on intersubunit associations.

These experiments also enabled us to measure p110-free p85s and the selectivity of intersubunit associations in vivo. By measuring the total moles of the different p110s in p85α^avi/avi^ or p85β^avi/avi^-pull-downs from MEFs ([Fig. 3*A*](#fig03){ref-type="fig"} and [*SI Appendix*, Fig. S11*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)) and various mouse tissues ([Fig. 3 *B* and *C*](#fig03){ref-type="fig"} and [*SI Appendix*, Fig. S11*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)), we could calculate the percentage of p110-free p85 in these contexts ([Fig. 3*D*](#fig03){ref-type="fig"}). This revealed that in liver and MEFs there is significant p110-free p85α and/or p85β.

![p110-free p85 is present in MEFs and certain murine tissues. (*A*) The absolute amounts of avi-tagged p85s compared with the amount of p110s recovered with them in streptavidin pull-downs from p85α^avi/avi^ or p85β ^avi/avi^ MEFs, corrected for input protein (means, ±SD, from two clones/genotype, each clone was measured three times). (*B* and *C*) Experiments like those in *A* except using tissues from mice expressing avi-tagged p85s and mBirA. Data are corrected for input protein (means ± SD, from three independent mice). (*D*) The percentage of total p110-free p85 in different mouse tissues was calculated from results shown in *A*--*C*. Statistically significant at \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001. NS, not significant. The underlying data are in [*SI Appendix*, Fig. S11](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental).](pnas.1803446115fig03){#fig03}

We also measured the stoichiometry of p85α and p85β found in individual p110-avi-pull-downs compared with their total concentrations in MEFs, and that of p110s found in individual p85-avi-pull-downs in mouse spleen or bone marrow (where p110δ is highly expressed) ([Fig. 4 *A* and *B*](#fig04){ref-type="fig"} and [*SI Appendix*, Figs. S11 and S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). These results indicated that p110α and p110β associate with p85α and p85β nonselectively. However, more p110δ is recovered with p85α than its concentration predicts and hence appears to bind p85α selectively. We independently confirmed these results by immunoblotting for p110δ and p85α in lysates from spleens (from p85α^avi/avi^ or p85β^avi/avi^ mice) before and after streptavidin-mediated pull-down ([Fig. 4*C*](#fig04){ref-type="fig"}).

![p85α and p110δ, but not other subunits, interact preferentially in vivo. (*A*) Compares the expected (e) and the measured (m), by streptavidin pull-down and mass spec, levels of the different class IA PI3K heterodimers in MEFs. Expected levels were calculated based on total p85 levels in the respective MEFs ([*SI Appendix*, Fig. S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)) accounting for the percentage of p85α or β not bound to p110 ([Fig. 3](#fig03){ref-type="fig"}); expressed as percentages of the total p85. Data are means ± SD, from two MEF clones/genotype. (*B*) The levels of p110 subunits bound to p85α or β in the bone marrow or spleen of mice expressing relevant avi-tagged PI3K constructs. The levels are expressed as percentages of the total p110 measured by mass spec. Data shown are means ± SD, from three mice. (*C*) The levels of p110δ in lysates of spleens from mice expressing mBirA and either avi-tagged p85α or β, before (pre) and after (post) streptavidin pull-down, as assessed by immunoblotting. Parallel immunoblots for p85α and βCOP, that control for the efficiency of pull-down and cell-input, are also shown. The data are from a typical experiment repeated twice. Statistically significant at \**P* \< 0.05, \*\**P* \< 0.01, and \*\*\**P* \< 0.001. NS, not significant.](pnas.1803446115fig04){#fig04}

PDGFRs are composed of PDGFRα and PDGFRβ subunit dimers and bind to class IA PI3K regulatory subunits through a pair of autophosphorylated tyrosine residues in the cytoplasmic kinase-insert domain. We measured ligand-dependent association of class IA PI3K subunits with PDGFRs in MEFs by immunoprecipitation (IP) of the receptors (with about 80--90% efficiency [Fig. 5*A*](#fig05){ref-type="fig"}) and immunoblotting or mass spectrometry with internal, heavy-peptide standards ([Fig. 5 *B--D*](#fig05){ref-type="fig"}). Very similar proportions of total p85α and p85β became associated with PDGFRs in PDGF-stimulated MEFs ([Fig. 5 *B--D*](#fig05){ref-type="fig"}), whether measured by immunoblotting or mass spectrometry (when the latter data were corrected for the absolute amounts of p85α and p85β in the MEFs, see [*SI Appendix*, Fig. S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). This was true across a range of doses of PDGF ([Fig. 5 *C* and *D*](#fig05){ref-type="fig"}) and suggests that PDGFRs have quantitatively similar interactions with p85α or p85β. Interestingly, following submaximal stimulation, p110α was recruited to activated PDGFRs five to six times more effectively than p110β (i.e., correcting for the cellular concentrations of the p110s, [Fig. 5 *B--D*](#fig05){ref-type="fig"} and [*SI Appendix*, Fig. S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). This result indicated that p110α-, compared with p110β-, containing class IA PI3K complexes are selectively recruited to activated PDGFRs. This selectivity appeared to be largely intrinsic to the PI3K-complexes, and not a result of, e.g., compartmentalization or associations that are not via SH2 domain:phospho-tyrosine interactions, as the proportions of endogenous PI3Kα and PI3Kβ in MEFs lysates were similarly, and almost completely, bound by excess concentrations of doubly tyrosine phosphorylated peptides based on activated murine PDGFRs (PYP, 5,000 fmol, [Fig. 5 *E* and *F*](#fig05){ref-type="fig"}).

![p110α is preferentially recruited to activated PDGFRs. (*A*) The levels of PDGFR α and β in MEF lysates (clone WT \#1) before (pre) and after (post) pull-down with anti-PDGFR Abs was measured by immunoblotting, with βCOP as a loading control. (*B*) Relative levels of PI3K subunits recruited to PDGFRs following stimulation with PDGF-BB (10 ng/mL for 1 min). Representative immunoblots before and after PDGFR pull-down (*Left*) and quantitation of each subunit's recruitment, as a percentage of its total level in that clone (clone WT \#1, [*SI Appendix*, Fig. S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). (*C*) The absolute levels of subunits recruited to PDGFRs following stimulation with different doses of PDGF-BB for 1 min, measured by mass spec. (*D*) "Raw" ratios of p110α/p110β and p85α/p85β associated with PDGFRs, based on measurements in *C*. Normalized ratios were calculated by dividing the raw ratios by the ratios of the total levels of those subunits in that clone of MEFs as calculated in [*SI Appendix*, Fig. S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental). (*E*) Absolute levels of p110α and p110β recovered with a PYP; the *Inset* shows the normalized (based on [*SI Appendix*, Fig. S12](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)) ratio of p110α/p110β recovered with tyrosine-phosphorylated peptides. (*F*) Immunoblots of PI3K subunits in lysates following pull-down with the PYPs or eluted from those pull-downs. The data are all means, ±SD, from three independent experiments.](pnas.1803446115fig05){#fig05}

These results suggest the catalytic subunits of class IA PI3Ks have a powerful impact on recruitment to tyrosine-phosphorylated proteins. The C-SH2 domain of p85 subunits bind (involving Y685 in p85α) and restrain the activity of p110β and δ-, but not p110α-, heterodimers in the absence of phospho-tyrosine docking ([@r8]). This might lead to the C-SH2 in PI3Kα having higher affinity for activated PDGFRs and hence could explain our results. To test this, we did experiments with recombinant PI3Kα and β in which recovery of wild-type-p85α-containing or Y685A-p85α-containing PI3Kα or PI3Kβ with biotinylated PYPs in streptavidin-pull-downs was measured. We found that Y685A-p85α-increased, compared with wild-type p85α, the recovery of p110β-, but not p110α-containing heterodimers ([*SI Appendix*, Fig. S13*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)), consistent with work measuring activation of similar constructs by PYPs ([@r8], [@r10]). However, we saw little difference between the recovery of the recombinant PI3Kα and PI3Kβ. This result was supported by equilibrium binding experiments that indicated recombinant PI3Kα and PI3Kβ have similar affinities for PYPs ([*SI Appendix*, Fig. S13*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). These results suggest that the apparently greater freedom of the C-SH2 domain in PI3Kα is not the prime reason for the higher recovery of endogenous PI3Kα than PI3Kβ with activated PDGFRs. We cannot explain the difference in the behavior of the endogenous and recombinant PI3Kα and β complexes in these assays. There may be posttranslational modifications to PI3Kα/β in MEFs that lead to PI3Kα having a relatively higher affinity for activated PDGFRs.

Quantitative analyses of class IA PI3K subunits in PDGFR-IPs from MEFs also found evidence for p110-free p85 ([Fig. 6 *A--C*](#fig06){ref-type="fig"} and [*SI Appendix*, Fig. S14](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). Because of the context of these assays, we could only measure the total, PDGFR-associated p110-free p85 but not the proportions that were p85α or p85β. Significantly, PDGFRs were enriched in p110-free p85, compared with heterodimeric p85, under basal unstimulated conditions and in the presence of low concentrations of PDGF ([Fig. 6 *A* and *B*](#fig06){ref-type="fig"}). Consistent with this, the proportion of p110-free p85β^avi/avi^ that could be recovered by streptavidin from lysates of p85β^avi/avi^-expressing MEFs was reduced by prior IP of PDGFRs ([Fig. 6*C*](#fig06){ref-type="fig"}). These results suggest that p110-free p85 has a higher affinity than heterodimeric-p85 for tyrosine-phosphorylated PDGFRs. This hypothesis was confirmed by in vitro binding experiments ([Fig. 6*D*](#fig06){ref-type="fig"}) which showed that p85α bound PYPs with higher affinity and co-operativity than p85α/p110α.

![p110-free p85 is recruited to PDGFRs with higher affinity than the p85-p110 dimers at low levels of receptor activation. (*A*) The amounts of p110-free p85 associated with PDGFRs following stimulation with PDGF-BB (1 min). Levels are expressed as a percentage of the total p85 associated with PDGFRs (as presented in [Fig. 5](#fig05){ref-type="fig"}). (*B*) Absolute amounts of p110-free p85 recovered with PDGFRs, quantified by mass spec ("measured") compared with the amount predicted if no difference in affinity, between p110-free and heterodimeric-p85, existed ("expected"). Expected values were calculated by multiplying the amount of total p85 recruited to PDGFR ([Fig. 5*C*](#fig05){ref-type="fig"}) with the percentage p110-unbound p85 in that clone ([Fig. 3*D*](#fig03){ref-type="fig"}). (*C*) Amounts of p110-free p85β in streptavidin pull-downs from MEFs expressing p85β^avi/avi^, with (+) or without (−) prior pull-down of PDGFRs. The amount is expressed as a percentage of the total amount of p85β pulled down or as absolute levels. (*D*) Estimating the apparent affinity of interaction between recombinant, purified, monomeric p85α or p85α-p110α dimers and PYPs using fluorescence polarization. A given protein preparation was equilibrated with a fluorescein-labeled PYP (Fluor-GpYMDMS, 2 nM) and a doubly phosphorylated, nonfluorescent PYP was titrated into the mixture to the indicated concentrations. The data are all means, ±SD, from three independent experiments. Statistically significant at \**P* \< 0.05 and \*\**P* \< 0.01.](pnas.1803446115fig06){#fig06}

PDGF stimulates a transient accumulation of PIP~3~ leading to phosphorylation of PKB in MEFs ([@r7], [@r29]). Activation of PKB has been shown to be substantially reduced, at lower doses of PDGF, in p110α^−/−^-, but not p110β^−/−^-, MEFs ([@r29], [@r30]). Given our results suggesting PI3Kα and β are both, although differentially, recruited to PDGFRs, we determined their roles in PDGF-stimulated PIP~3~ accumulation in MEFs. BYL-719 inhibited PIP~3~ accumulation ([Fig. 7*A*](#fig07){ref-type="fig"}) by about 60% at concentrations that are likely to be PI3Kα-selective (\<1 μM). TGX-221, at concentrations consistent with its action being on PI3Kβ (\<0.1 μM), inhibited PIP~3~ accumulation ([Fig. 7 *A* and *B*](#fig07){ref-type="fig"}) by about 40%. This inhibition was manifest across a range of PDGF concentrations ([Fig. 7*B*](#fig07){ref-type="fig"}) and further increased by a submaximal inhibitory dose of PI3Kα-selective inhibitor ([Fig. 7*A*](#fig07){ref-type="fig"}). Interestingly, although TGX-221 inhibited PDGF-stimulated PKB phosphorylation, it did so only at lower concentrations of PDGF ([Fig. 7*C*](#fig07){ref-type="fig"}), consistent with previous data ([@r30]) and the idea that PKB phosphorylation can be maximally activated by submaximal amounts of PIP~3~. These results suggest that PI3Kα and PI3Kβ are both activated by PDGFRs and that they have both unique and overlapping roles in PIP~3~ accumulation.

![Despite a relatively small amount of PI3Kβ being associated with activated PDGFRs, it generates a more substantial proportion of the PIP~3~ that accumulates. (*A*) Inhibition of PDGF-stimulated (PDGF-BB, 10 ng/mL, 1 min) PIP~3~ accumulation by p110α-selective (BYL-719) and/or p110β-selective (TGX-221) inhibitors in MEFs. The data are means, ±SD, from three experiments. (*B*) Impact of TGX-221 on PIP~3~ levels following stimulation with various doses of PDGF-BB for 1 min. The data are means, ±SD, from three experiments. (*C*) Impact of TGX-221 on phosphorylation of PKB following stimulation with various doses of PDGF-BB for 1 min assessed by immunoblotting with anti-phospho- T308 or S473-antibodies. Results were corrected for cell input using βCOP and expressed as percentages of P-PKB following 10 ng/mL PDGF-BB. The data are means, ±SEM, from two experiments. \**P* \< 0.05, \*\**P* \< 0.01 (*t* test, two-sample equal variance, two-sided distribution).](pnas.1803446115fig07){#fig07}

The quantitatively similar roles of PI3Kα and PI3Kβ in PIP~3~ accumulation contrasted with the preferential recruitment of PI3Kα to PDGFRs. To understand if this was a result of a difference in their regulation by small GTPases, we obtained MEFs from mice expressing small-GTPase-insensitive, point-mutant knock-ins of p110α and p110β \[Ras-insensitive-p110α, p110α^T208D,^ ^K227A/T208D,^ ^K227A^ ([@r7]) and Rac/CDC42-insensitive-p110β, p110β^S205D,^ ^K224A/S205D,^ ^K224A^ ([@r6])\]. Mice, and MEFs derived from them, expressing these constructs have been used to reveal important roles for the RBDs of PI3Ks α & β in tumourigenesis and some G protein-coupled receptor (GPCR) signaling via class I PI3Ks ([@r6], [@r7]). We measured PDGF-stimulated PIP~3~ accumulation in these MEF lines and the association, of both the wild-type and small-GTPase-insensitive versions, of p110α and p110β with PDGFRs. We found that the RBD of p110α was not needed for PDGF-stimulated PIP~3~ accumulation ([Fig. 8*A*](#fig08){ref-type="fig"}), consistent with previous work measuring PKB phosphorylation ([@r7]). In contrast, the RBD of p110β was required for maximal PDGF-stimulated PIP~3~ accumulation \[[Fig. 8 *B* and *C*](#fig08){ref-type="fig"}; work indicating the RBD of p110β is not required for PDGF-stimulated AKT phosphorylation ([@r6]) used 5 min stimulations and is entirely consistent with our results showing the role of the RBD is reduced at later times, [Fig. 8*B*](#fig08){ref-type="fig"})\]. A comparison of the effect of a PI3Kβ-selective inhibitor on PDGF-stimulated PIP~3~ accumulation in MEFs expressing either wild-type- or Rac/CDC42-insensitive versions of p110β, suggested that p110β is substantially dependent on its RBD in this context ([Fig. 8*C*](#fig08){ref-type="fig"}).

![The RBD domain of p110β is necessary for PIP~3~ production but not for binding to activated PDGFRs. (*A*) PDGF-stimulated (PDGF-BB, 10 ng/mL, 1 min) PIP~3~ accumulation in MEFs expressing wild-type (WT) or Ras-insensitive p110α (RBDα). Results are expressed as percentage of the PIP~3~ levels in the respective, wild-type (WT) line. The data are means, ±SEM, from three experiments. (*B*) PIP~3~ accumulation in MEFs expressing WT or Rac/CDC42-insensitive p110β (RBDβ). Data are expressed as in *A*. The amount of PIP~3~ that accumulated in MEFs expressing RBDβ, but not RBDα, was significantly lower than their WT controls (*P* = 0.011, two-way ANOVA). (*C*) PIP~3~ levels in PDGF-stimulated (PDGF-BB, 10 ng/mL, 1 min) WT or RBDβ-MEFs in the presence, or absence, of TGX-221 (100 nM). Results are expressed as percentage of the PIP~3~ levels measured in the respective WT-MEFs in the absence of inhibitor. The data presented are means, ±SD, from three experiments, TGX-221 significantly inhibited the response in WT- (*P* = 0.03, ratio paired *t* test) and RBDβ-MEFs (*P* = 0.03, ratio paired *t* test). (*D*) The absolute amounts of p110α or p110β recruited to activated PDGFRs (PDGF-BB, 10 ng/mL for 1 min) in RBDβ- or WT-MEFs. The data are presented as means, ±SD, from three experiments, the amount of p110β associated with the activated PDGFRs was significantly lower than p110α (*P* = 0.00003 in WT and 0.0027 in RBDβ-MEFs; *t* test, two-sample equal variance, two-sided distribution); however, the association of neither p110α nor p110β was significantly changed in the context of the RBDβ mutant construct. The data underlying *D* is shown in [*SI Appendix*, Fig. S15](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental).](pnas.1803446115fig08){#fig08}

To understand the role of the RBD in p110α and p110β association with, and activation by, PDGFRs we measured the recovery of these constructs with PDGFRs by mass spectrometry. We found that the ligand-stimulated association of p110α with PDGFRs was not dependent on its RBD's ability to bind to Ras ([Fig. 8*D*](#fig08){ref-type="fig"} and [*SI Appendix*, Fig. S15](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). These results confirm previous work indicating neither growth factor-stimulated PKB phosphorylation nor association of p85s with tyrosine-phosphorylated proteins are dependent on Ras binding to the RBD of p110α ([@r7]). Surprisingly, however, the results also showed that despite the very clear role for the RBD of p110β in PDGF-stimulated PIP~3~ accumulation, it had no role in binding of PI3Kβ to PDGFRs. The simplest explanation for these results is that Ras does not contribute to activation of PI3Kα at PDGFRs, whereas binding of active Rac/CDC42 is absolutely required for stimulation, but not binding, of PI3Kβ at PDGFRs.

Discussion {#s2}
==========

Our results show that p85α and p85β bind p110α or p110β with indistinguishable affinity in vivo and hence the concentrations of the heterodimers they can form are solely a function of the relative levels of the subunits. Interestingly, p110δ preferentially complexes with p85α compared with p85β. These results suggest that PI3Kδ is hard-wired to use p85α- or avoid p85β-specific properties or functions; e.g., phosphorylation ([@r15]) or p85β-directed ([@r18]) or 85α-directed ([@r23]) ubiquitination and degradation. It is noteworthy that the phenotypes of mice lacking p85α or expressing kinase-dead p110δ are most similar in B lymphocytes where PI3Kδ is dominant ([@r31], [@r32]). Hence our data resolve an important long-standing question about the rules of engagement in class IA PI3K signaling ([@r9]).

We find that p85α and p85β contribute very similar PDGFR-binding capabilities to class IA PI3Ks. This is consistent with the known similarities in phospho-peptide-binding properties of the N and C-terminal SH2 domains within and between class IA PI3K regulatory proteins ([@r3]). Reported differences in the properties of p85α and p85β, in different contexts ([@r4], [@r5]), are presumably due to other interactions and/or domains.

Our data, derived from analysis of both p85- and PDGFR-pull-downs, suggest that p110-free p85α and p85β are present in mouse tissues and cells. This provides direct, independent support for recent work identifying roles for p110-free p85s ([@r19], [@r21], [@r22]). p110-free p85s have higher affinity and more co-operative binding to tyrosine-phosphorylated proteins than heterodimeric p85 proteins. This property could allow relatively small amounts of p110-free p85s to compete effectively with heterodimeric PI3Ks for low-abundance phosphorylated YXXM motifs. This may explain their relative enrichment on PDGFRs in basal or weakly stimulated cells and suggests they may have a role in reducing basal RTK signaling noise and/or in setting a threshold level of receptor activation that must be achieved to drive class IA PI3K activation. The stoichiometry of p85s to potential phospho-tyrosine binding sites will be an important determinant of the impact of p110-free p85s on PI3K signaling. A large excess of tyrosine-phosphorylated "YXXM" proteins over p85s would suggest that the window in which p110-free p85 might act as an inhibitor would be very limited. The stoichiometry with which tyrosine residues in endogenous proteins are phosphorylated is difficult to measure. However, given that a number of YXXM-containing signaling proteins seem to have similar copies per cell as p85s \[PDGFRs, EGFRs, insulin receptor substrates (IRSs) in MEFs are all in the range 1 × 10^4^-2 × 10^5^ compared with 10^5^ p85s\] and maximal PDGFR activation leads to over 80% of total p85 associating with anti-PDGFR-IPs ([Fig. 5 *B* and *C*](#fig05){ref-type="fig"}), it seems that upon intense challenge there will be an excess of phosphorylated YXXM motifs and depletion of cytosolic p85s. Hence, p110-free p85 could act to tune the threshold, but not the maximal, activation of class IA PI3K signaling.

Although PI3Kα played the major role in PDGF-stimulated PIP~3~ synthesis, PI3Kβ generated a disproportionately larger amount than predicted by its association with PDGFRs. We speculated this might be a result of a difference in other signals integrated by PI3Kα and PI3Kβ. Our data show that binding of active Ras to the RBD of p110α is not needed for PDGF-stimulated association of PI3Kα with PDGFRs or for PIP~3~ accumulation. In contrast, the equivalent binding of Rac/CDC42 to the RBD of p110β is required for PDGF-stimulated PI3Kβ-dependent PIP~3~ accumulation but not for association of PI3Kβ with PDGFRs. The simplest explanation of the latter results is that, in vivo, PI3Kβ is extremely dependent on combined activation by Rac/CDC42 and the activated PDGFR, in line with a previous hypothesis ([@r33]). The two inputs to PI3Kβ could be engaged in any order. The most parsimonious explanation of our data is that they act sequentially, because of a requirement for PI3Kβ to be associated with PDGFRs to become sensitive/accessible to Rac/CDC42 ([@r34]). In this model, the role of Rac/CDC42 might be to allow PDGFR-associated PI3Kβ access to PI(4,5)P~2~.

Our results resolve some long-standing questions and also raise further questions regarding the origin of the selective interaction between p85α and p110δ and the physiological purpose of p110-free p85α and p85β. It will also be important to extend our studies describing preferential recruitment of PI3Kα versus PI3Kβ to tandem phospho-tyrosines in PDGFRs to other contexts involving different local sequences and numbers of phospho-tyrosine binding sites.

Materials and Methods {#s3}
=====================

Generation of PI3K-Avi-Tag and mBirA Mice. {#s4}
------------------------------------------

*Pik3ca*-avi, *Pik3cb*-avi, *Pik3cd*-avi, *Pik3r1*-avi, *Pik3r2*-avi, and *Rosa26*-mBirA targeting vectors were generated by a combination of cloning, recombineering, and gene synthesis and used to generate mice expressing avi-tagged PI3K subunits homozygotes (except live p110α^avi/avi)^) and *Rosa26*-mBirA heterozygotes on a pure C57BL/6J background by standard ES cell manipulation and breeding ([*SI Appendix*, *Materials and Methods* and Figs. S1--S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)). The Babraham Institute's Animal Welfare and Ethical Review Body, which includes veterinary experts and members of the public, approved the animal experiments described in the manuscript.

MEF Preparation, Cell Culture, and Lysis. {#s5}
-----------------------------------------

Primary MEFs were derived from 14.5 d old embryos and immortalized with SV40T ([*SI Appendix*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental)).

Growth Factor Stimulations. {#s6}
---------------------------

MEFs were serum-starved 16 h then stimulated with recombinant murine PDGF-BB with doses and for times indicated in the figures. PI3Ks inhibitors were added 20 min before stimulation.

Quantification of PI(3,4,5)P~3~. {#s7}
--------------------------------

Lipid extraction and absolute quantitation of PI(3,4,5)P~3~ levels in 2 × 10^5^ cell aliquots of MEFs were analyzed by published methods ([@r35]).

Pull-Down of Class IA PI3K with PYPs. {#s8}
-------------------------------------

PI3Ks were recovered from MEF lysates using a synthetic, biotinylated, doubly phosphorylated peptide derived from murine PDGFR (PYP, residues 735--767) and streptavidin-mediated pull-down.

Association of Recombinant PI3K Complexes with PYPs. {#s9}
----------------------------------------------------

Recombinant PI3K heterodimers (p85α/p110α, p85α/p110β, p85α-Y685A/p110α, and p85α-Y685A/p110β) were expressed in Sf9 cells, purified, and various amounts were incubated with biotin-labeled doubly phosphorylated PYP, pulled down with streptavidin beads, and the associated p85α was quantified by immunoblotting with fluorescent 2^0^ antibodies as described in the [*SI Appendix*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental).

Matters only Described in the [*SI Appendix*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803446115/-/DCSupplemental). {#s10}
-----------------------------------------------------------------------------------------------------------------------------

Antibodies and Reagents. Immunoblotting. Streptavidin-and antibody-mediated pull-down. Sample preparation and analysis by mass spectrometry and absolute protein quantitation. Preparation of recombinant PI3Ks. Competition Assays with PYPs. Statistics.
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